Month: January 2026

Diginex Limited Announces Signing of Definitive Agreement to Acquire Plan A, Creating One of Europe’s Leading Integrated ESG, Carbon Accounting and Decarbonization Platforms

Written by Customer Service on January 7, 2026. Posted in Mergers And Acquisitions.

The combined business will deliver a single sophisticated platform to expand beyond existing strategic relationships, including HSBC, Coca Cola, Visa, and BMW. LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) — Diginex Limited (NASDAQ: DGNX), a leading provider of Sustainability RegTech and data management solutions, today announced the signing of a definitive share purchase and transfer agreement (the “SPTA”), to acquire PlanA.earth GmbH (“Plan A”), one of Europe’s leading AI-powered carbon accounting and decarbonization platforms. The SPTA provides that Diginex will deliver to the sellers of Plan A €3 million in cash and 6,720,317 shares of Diginex’s ordinary shares valued at €52 million in exchange for 100% of the equity of Plan A. With this transaction, Diginex warmly welcomes Visa, Deutsche Bank, as shareholders, and...

Mixie Technologies, Inc. (PHCG), formerly Pure Harvest Corporate Group, Secures Minority Ownership Stake in HoloTwin LLC

Written by Customer Service on January 7, 2026. Posted in Mergers And Acquisitions.

Acquisition solidifies Mixie’s expansion into AI-driven digital twin solutions and supports partner-centric scaling across infrastructure, energy, security, and wiring ecosystems DENVER, Jan. 07, 2026 (GLOBE NEWSWIRE) — Mixie Technologies, Inc. (OTC: PHCG), formerly known as Pure Harvest Corporate Group, Inc. (“Mixie” or the “Company”), today announced that it has closed on the acquisition of a 25% minority interest in HoloTwin LLC (“HoloTwin”) through the execution and simultaneous closing of the definitive agreements originally contemplated in the binding Letter of Intent disclosed earlier this month. Completion of this acquisition represents an important step in Mixie’s evolution into a platform-based technology company focused on scalable, recurring revenue solutions powered by AI, spatial data, and digital twin infrastructure....

UniFirst Announces Financial Results for the First Quarter of Fiscal 2026

Written by Customer Service on January 7, 2026. Posted in Earnings Releases And Operating Results.

WILMINGTON, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) — UniFirst Corporation (NYSE: UNF) (“UniFirst” or the “Company”) today reported results for its fiscal 2026 first quarter ended November 29, 2025. First Quarter 2026 Consolidated ResultsConsolidated revenues increased 2.7% to $621.3 million compared to $604.9 million in the first quarter of fiscal 2025, driven by organic growth in the core Uniform & Facility Service Solutions segment. Operating margin was 7.3% compared to 9.2% in the prior year period, reflecting planned investments in growth and digital transformation initiatives. Net income was $34.4 million compared to $43.1 million in the prior year period and diluted earnings per share was $1.89 compared to $2.31 in the prior year period. Adjusted EBITDA margin was 13.3% compared to 15.5% in the prior year period. The...

Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108

Written by Customer Service on January 7, 2026. Posted in Public Companies.

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) Carlsbad, CA, Jan. 07, 2026 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that the Crohn’s & Colitis Foundation (the “Foundation”), through its IBD Ventures program, has approved a strategic equity investment of up to $500,000 in Palisade. The investment will support the continued clinical and mechanistic development of PALI-2108, the Company’s lead gut-microbiota-activated...

Worthington Enterprises Participating in CJS Securities New Ideas for the New Year Conference

Written by Customer Service on January 7, 2026. Posted in Public Companies.

COLUMBUS, Ohio, Jan. 07, 2026 (GLOBE NEWSWIRE) — Worthington Enterprises (NYSE: WOR), a designer and manufacturer of market-leading brands that improve everyday life by elevating spaces and experiences, today announced that it will participate in next week’s CJS Securities New Ideas for the New Year conference. The virtual presentation is scheduled for Wednesday, January 14 at 8:45 a.m. ET. Please click here to register. President and Chief Executive Officer Joe Hayek and Chief Financial Officer Colin Souza will share the company’s strategy for accelerating growth and shareholder value through the lens of the proven Worthington Business System of innovation, transformation and M&A. A replay of the session will be posted in the Investor Relations section of the Worthington Enterprises website. About Worthington Enterprises...

Partial Withdrawal of Letter of Intent – IDOX plc – 07 01 2026 – (CGAML)

Written by Customer Service on January 7, 2026. Posted in Mergers And Acquisitions.

Letter of Intent: Acquisition of IDOX plc by Frankel UK Bidco Limited On 28th October 2025, Canaccord Genuity Asset Management Limited provided a Letter of Intent regarding our intentions in relation to 10,480,000 shares. In accordance with The City Code on Takeovers and Mergers, Rule 2.10 (c)(i), we advise that we have disposed of 500,000 shares. Consequently, we are no longer able to accept or procure the acceptance of the Offer, in relation to those shares. Our intention in respect of the remaining 9,980,000 shares is now as described in the original Letter of Intent. Mark ElliottInvestment Controls AnalystCanaccord Genuity Wealth Management

SeaStar Medical Announces 2026 Milestones

Written by Customer Service on January 7, 2026. Posted in Public Companies.

Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical’s first-in-class SCD therapy for the adult AKI indication – a potential $4.5 billion market – through completion of enrollment of the NEUTRALIZE-AKI pivotal trial and initiation of the PMA process Progress the clinical development of the SCD therapy in patients with severe heart failure Leverage rapid pathways to commercialization of the SCD therapy through additional FDA Humanitarian Use and Breakthrough Device Designations DENVER, Jan. 07, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today its key milestones...

ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus

Written by Customer Service on January 7, 2026. Posted in Public Companies.

Conference Call Scheduled for Friday, January 9, 2026 at 9:00 AM ET PORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, plans to conduct a conference call with investors on Friday, January 9, 2026 at 9:00 AM ET. The Company first announced a strategic change in focus in favor of the First Defense® product line and away from Re-Tain® on December 24, 2025. The Company will also discuss its unaudited topline sales results for the fourth quarter and full year ended December 31, 2025, which will be announced after the market closes on Thursday, January 8, 2026. Conference Calls:The Company is planning to host a conference call on Friday, January 9, 2026...

Foresight: Eye-Net to Showcase its Innovative V2X Collision Prevention Technology at CES 2026 in Las Vegas

Written by Customer Service on January 7, 2026. Posted in Public Companies.

Beyond line-of-sight V2X technology protects vulnerable road users in connected and autonomous mobility Ness Ziona, Israel, Jan. 07, 2026 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, today announced that its majority-owned subsidiary, Eye-Net Mobile Ltd. (“Eye-Net”), will participate in CES 2026 in Las Vegas and will showcase its commercially-ready vehicle-to-everything (“V2X”) collision prevention technology. By leveraging existing cellular infrastructure, Eye-Net’s proprietary V2X collision prevention technology enables real-time communication between vehicles and vulnerable road users, including pedestrians and cyclists. Eye-Net’s innovative approach to delivering early alerts about cross collision addresses a fundamental...

Ethos and North American Collaborate to Offer Accumulation Indexed Universal Life Product

Written by Customer Service on January 7, 2026. Posted in Public Companies.

AUSTIN, Texas and DES MOINES, Iowa, Jan. 07, 2026 (GLOBE NEWSWIRE) — Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a partnership with North American Company for Life and Health Insurance®, introducing a proprietary Accumulation Indexed Universal Life product (IUL) to Ethos’ digital life insurance platform. North American will be a new provider for the Ethos IUL product suite, providing eligible consumers with life insurance coverage up to $2 million. Ethos and North American’s Accumulation IUL brings strong performance, differentiated benefits, and a faster, simpler process for agents and consumers alike. This new IUL can offer an instant-decision with no medical exams1. Once approved, consumers can secure meaningful coverage in minutes, without medical...

Month: January 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals